October 23rd 2024
During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
September 20th 2024
September 19th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Phase 3 Study of Imtelstat Versus BAT Explores Survival Improvement in Myelofibrosis
April 15th 2021A phase 3 study with the goal of demonstrating overall survival benefit with imetelstat versus best available therapy in patients with refractory myelofibrosis has dosed the first patient with the experimental agent.
Read More
Study Identifies Ideal Ixazomib Triplet Regimen for Newly Diagnosed Multiple Myeloma
April 15th 2021Ixazomib plus cyclophosphamide, and dexamethasone elicited higher rates of efficacy compared with ixazomib/dexamethasone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma/
Read More
Expert Perspectives on a 75-Year-Old Woman With Triple-Class Refractory Multiple Myeloma
April 14th 2021Adriana Rossi, MD, describes the treatment approach in caring for a 75-year-old woman with triple-class refractory multiple myeloma [RRMM] while highlighting results from the relevant DREAMM and SOHO studies.
Watch
Copanlisib Plus Rituximab Extends Progression-Free Survival in Indolent NHL
April 10th 2021Primary results from the phase 3 CHRONOS-3 study revealed a survival benefit with the combination of copanlisib in combination with rituximab over rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.
Read More
A 75-Year-Old Man With Multiple Myeloma
April 7th 2021A key opinion leader in hematology, Jonathan Kaufman, MD, provides insight into the case of a 75-year-old man with multiple myeloma and discusses treatment considerations, standard of care therapies, and recent clinical trial updates for the management of multiple myeloma.
Watch
Tuscano Reviews Treatment and Toxicity Management for a Patient With Classic Hodgkin Lymphoma
April 5th 2021Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.
Read More
FDA Approval Sought for Pacritinib to Treat Patients with Myelofibrosis and Severe Thrombocytopenia
April 1st 2021A rolling submission of a New Drug Application has been completed for pacritinib which is seeking FDA approval as a treatment for patients with myelofibrosis who have severe thrombocytopenia.
Read More
FDA Approves Isatuximab With Carfilzomib and Dexamethasone for Adults With R/R Multiple Myeloma
March 31st 2021The FDA has granted approval to the combination of isatuximab added to carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
Read More
Givinostat Shows Promise for Long-Term Use in Patients With Polycythemia Vera
March 31st 2021In patients with polycythemia vera, long-term use of the histone deacetylase inhibitor givinostat may be warranted after the agent demonstrated tolerable safety and good efficacy over a 4-year period in an ongoing, multicenter, open-label, single-arm study of patients with a chronic myeloproliferative neoplasm who are positive for a JAK2 V617F mutation.
Read More